Basic Arcoxia Information

• International Nonproprietary Name (INN): Etoricoxib
• Brand names available in Australia: Arcoxia, Exinef, Nucoxia
• ATC Code: M01AH05
• Forms & dosages: Tablets (30 mg, 60 mg, 90 mg, 120 mg)
• Manufacturers in Australia: Merck Sharp & Dohme
• Registration status in Australia: Approved, prescription-only (Rx)
• OTC / Rx classification: Prescription only

Critical Warnings & Restrictions

When considering the use of Arcoxia (Etoricoxib), it's essential to understand the critical warnings and restrictions that apply, especially for specific demographic groups. Patients who are elderly, pregnant, or those with chronic illnesses need careful monitoring due to increased risks of complications from this medication.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

The elderly are particularly vulnerable when taking Arcoxia, as they may have pre-existing conditions or take multiple medications that could interact adversely. This age group is at a higher risk for cardiovascular and gastrointestinal events, making it essential to monitor their health closely while on treatment.

Pregnant women also face heightened risks, as Arcoxia is not recommended during pregnancy due to potential harm to the fetus. Anyone with chronic illnesses, including liver or kidney conditions, may require dosage adjustments and regular health checks to mitigate risks associated with the drug.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Arcoxia can impact daily activities, notably driving and workplace safety. Patients may experience side effects such as dizziness, which can impair their ability to operate vehicles safely. It’s crucial to assess personal response to the medication before engaging in activities requiring full attention.

Q&A — “Can I Drive After Taking It in Australia?”

While many patients can drive after taking Arcoxia, those experiencing side effects, particularly dizziness, should avoid driving and operating heavy machinery. Always prioritise safety over convenience.

Before starting Arcoxia, particularly for chronic pain or inflammatory conditions like arthritis, it is crucial for patients to be fully informed about these potential complications and the importance of monitoring their health regularly. It is also recommended to discuss any previous health issues or current medications with a healthcare provider to ensure safe usage of Arcoxia.

Usage Basics

Are you looking for a way to manage your pain effectively? Do you have questions about how to use Arcoxia? Understanding the basics of this medication can greatly enhance your treatment experience.

INN, brand names available in Australia

The **International Nonproprietary Name (INN)** for Arcoxia is **Etoricoxib**. This medication is marketed under several brand names worldwide, with **Arcoxia** being the most recognized in Australia. Manufactured by Merck/MSD, Arcoxia is commonly available in various dosages, including:

• 30 mg
• 60 mg
• 90 mg
• 120 mg

Typically packaged in boxes containing 7, 14, 28, or 30 film-coated tablets, Arcoxia is designed for easy dosing. For those seeking alternatives, other brands like **Exinef** and **Nucoxia** are marketed in different regions, although Arcoxia holds a prominent position in the Australian market.

Legal classification (TGA-approved, PBS-listed)

In Australia, Arcoxia is classified as a **prescription-only** medication. It has received **TGA (Therapeutic Goods Administration)** approval, ensuring its safety and efficacy for patients requiring anti-inflammatory treatment. Additionally, Arcoxia is **listed on the Pharmaceutical Benefits Scheme (PBS)**. This listing makes it accessible for patients with specific eligibility criteria, allowing them to receive the medication at a subsidised cost. The stringent regulatory approval process underscores the importance of ensuring that patients receive medications that are both effective and safe.

Dosing Guide

Standard regimens (PBS reference dosing)

When it comes to managing various conditions, the PBS guidelines recommend specific dosing regimens for Arcoxia, also known as Etoricoxib, to ensure optimal patient outcomes. Here’s a quick rundown of the typical adult doses based on the indicated condition:

• Osteoarthritis: 60 mg once daily
• Rheumatoid arthritis: 90 mg once daily
• Ankylosing spondylitis: 90 mg once daily
• Acute gouty arthritis: Up to 120 mg once daily (maximum use of 8 days)
• Primary dysmenorrhea/Acute pain: 120 mg once daily (for short-term use: 1–5 days)
• Dental/Postoperative pain: 90–120 mg as a single dose or for 1–3 days

These dosing strategies help balance efficacy while aiming to minimise side effects, a crucial factor when considering patients’ overall health and quality of life.

Adjustments for comorbidities

Patients often possess a mix of health issues requiring careful attention to dosing adjustments.

For those with liver impairment, the guidance varies:

• Mild impairment: A maximum of 60 mg daily is acceptable.
• Moderate impairment: Reduced to a maximum of 30 mg daily.
• Severe impairment: Should be avoided altogether (contraindicated).

Renal function also plays a critical role:

• Severe renal impairment (creatinine clearance <30 mL/min) should not use Arcoxia.
• Mild to moderate renal impairment does not require adjustments but warrants close monitoring.

Older adults typically do not need dose adjustments, but continuous assessment of renal, cardiac, and hepatic function is key to ensuring their safety.

Q&A — “What if I miss a dose?”

If a dose is missed, the first step is to take it as soon as remembered. However, if it's nearly time for the next dose, the missed one should be skipped. Doubling up is a big no-no! This simple guideline helps maintain therapeutic levels without risking overdose and potential side effects.

Delivery Information

This efficient dispatch process ensures that patients can reliably access Arcoxia medication, offering significant improvements in managing conditions like arthritis and gout. Accessibility and proper dosing can markedly enhance treatment outcomes.